Live Breaking News & Updates on Neurocrine Ingrezza
Stay updated with breaking news from Neurocrine ingrezza. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Ben Glickman Neurocrine Biosciences and Lupin resolved patent litigation related to Neurocrine's Ingrezza medication. Lupin will have the right to sell. ....
Nachricht vom 23.07.2021 | 07:00 Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps DGAP-News: BB BIOTECH AG / Key word(s): Half Year Report/Interim Report 23.07.2021 / 07:00 Media release of July 23, 2021 Interim report of BB Biotech AG as at June 30, 2021 Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps Inflation moved higher during the second quarter as the economic recovery gathered steam, triggering temporary outflows of investor capital from growth sectors. Central banks signaled that the rise in inflation would be short-lived, after which capital began to flow back into tech and healthcare stocks. BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021. Their total return for the first half of 2021 including the dividend payout was 22.2% in CHF and 21.3% in EUR. BB Biotech took profi ....